Andrew FarnuminVariant BioEvotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis TreatmentsPress release details collaboration aimed at addressing unmet medical need in fibrotic indicationsApr 18Apr 18
Andrew FarnuminVariant BioTaking Stock: Two Years Into Variant Bio’s Unique Benefit-Sharing ProgramA summary of the work Variant Bio has done to date to ensure short-term benefits are rolled out around the worldJan 9, 2023Jan 9, 2023
Andrew FarnuminVariant BioAnnouncing Variant Bio’s Affordable Medicines PledgeHow we are expanding our commitment to sharing the benefits of research with partner communities around the worldOct 26, 2022Oct 26, 2022
Andrew FarnuminVariant BioVariant Bio Finalizes Series B FinancingOur mission at Variant Bio is to develop life-saving therapies by studying the genetics of diverse populations that are outliers for…Nov 12, 2021Nov 12, 2021
Andrew FarnuminVariant BioVariant Bio Announces Formal Commitment to Benefit SharingHow we are breaking ground in genomics research by guaranteeing benefits for our partner communitiesNov 11, 2020Nov 11, 2020
Andrew FarnuminVariant BioVariant Bio Finalizes Series A FinancingInvestors include Lux Capital, Alta Partners, Casdin Capital, Sahsen Ventures, and Alexandria Venture InvestmentsAug 12, 2020Aug 12, 2020
Andrew FarnuminVariant BioVariant Bio: A New Model for Genomic Research PartnershipsOur new CEO, Andrew Farnum, discusses how we are innovating research through benefit-sharing and transparencyJul 22, 2020Jul 22, 2020
